286 related articles for article (PubMed ID: 27376180)
1. Patients Receiving Parenteral Bisphosphonates for Malignant Disease and Having Developed an Atypical Femoral Fracture Are at Risk of Concomitant Osteonecrosis of the Jaw: An Evidence-Based Review.
Graves LL; Bukata SV; Aghazadehsanai N; Chang TI; Garrett NR; Friedlander AH
J Oral Maxillofac Surg; 2016 Dec; 74(12):2403-2408. PubMed ID: 27376180
[TBL] [Abstract][Full Text] [Related]
2. Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database.
Bejhed RS; Kharazmi M; Hallberg P
Ann Pharmacother; 2016 Aug; 50(8):616-24. PubMed ID: 27179251
[TBL] [Abstract][Full Text] [Related]
3. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
[TBL] [Abstract][Full Text] [Related]
4. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Sánchez A; Blanco R
Osteoporos Int; 2017 Mar; 28(3):1145-1147. PubMed ID: 27866217
[TBL] [Abstract][Full Text] [Related]
6. Risk of atypical femoral fractures and osteonecrosis of the jaw associated with alendronate use compared with other oral bisphosphonates.
Kharazmi M; Hallberg P; Warfvinge G; Michaëlsson K
Rheumatology (Oxford); 2014 Oct; 53(10):1911-3. PubMed ID: 25099769
[No Abstract] [Full Text] [Related]
7. Antiresorptive Therapies for Osteoporosis.
Weinerman S; Usera GL
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):555-60. PubMed ID: 26412797
[TBL] [Abstract][Full Text] [Related]
8. Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis?
Giovannacci I; Meleti M; Manfredi M; Mortellaro C; Greco Lucchina A; Bonanini M; Vescovi P
J Craniofac Surg; 2016 May; 27(3):697-701. PubMed ID: 27092912
[TBL] [Abstract][Full Text] [Related]
9. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
10. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
11. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy.
Chang ST; Tenforde AS; Grimsrud CD; O'Ryan FS; Gonzalez JR; Baer DM; Chandra M; Lo JC
Bone; 2012 Sep; 51(3):524-7. PubMed ID: 22634175
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
[TBL] [Abstract][Full Text] [Related]
13. A Case Report of Oral Bisphosphonate Treatment for Osteoporosis Leading to Atypical Femoral Fracture and Pathologic Mandibular Fracture.
Fernandes TL; Viezzer Fernandes B; Jitumori C; Franco GCN
Am J Case Rep; 2023 Oct; 24():e941144. PubMed ID: 37867315
[TBL] [Abstract][Full Text] [Related]
14. Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.
Galis B; Zajko J; Hirjak D; Vanko L; Kupcova I; Jurkemik J; Gengelova P; Mikuskova K; Halmova K; Riznic M; Czako L
Bratisl Lek Listy; 2017; 118(12):724-731. PubMed ID: 29322803
[TBL] [Abstract][Full Text] [Related]
15. ATYPICAL FEMORAL FRACTURES AFTER LONG-TERM BISPHOSPHONATES THERAPY: CASE REPORT.
Găleşanu C; Mocanu V; Buzdugă C; Florescu A; Zaharia V; Lisnic V
Rev Med Chir Soc Med Nat Iasi; 2016; 120(1):114-8. PubMed ID: 27125082
[TBL] [Abstract][Full Text] [Related]
16. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
[TBL] [Abstract][Full Text] [Related]
17. Gender related difference in the risk of bisphosphonate associated atypical femoral fracture and osteonecrosis of the jaw.
Kharazmi M; Hallberg P; Michaëlsson K
Ann Rheum Dis; 2014 Aug; 73(8):1594. PubMed ID: 24788545
[No Abstract] [Full Text] [Related]
18. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
19. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.
Aljohani S; Fliefel R; Ihbe J; Kühnisch J; Ehrenfeld M; Otto S
J Craniomaxillofac Surg; 2017 Sep; 45(9):1493-1502. PubMed ID: 28687467
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the jaw induced by bisphosphonates therapy in bone metastases patient: Case report and literature review.
Hao L; Tian Z; Li S; Yan K; Xue Y
Oral Oncol; 2022 May; 128():105852. PubMed ID: 35439709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
